Skip to content
Citicoline
Citicoline is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06B: Psychostimulants, agents used for adhd and nootropics
— N06BX: Other psychostimulants and nootropics in atc
— N06BX06: Citicoline
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlaucomaD005901EFO_0000516H40———134
Bipolar disorderD001714EFO_0000289F30.9———213
Cerebral infarctionD002544I63——11—2
Cocaine-related disordersD019970F14——11—2
Ischemic optic neuropathyD018917EFO_1000809H47.01———2—2
AlcoholismD000437EFO_0003829F10.1———2—2
DeliriumD003693R41.0———1—1
Neural conductionD009431———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Traumatic brain injuriesD000070642S06—11—13
Ischemic strokeD0000832421—1——2
StrokeD020521EFO_0000712I63.9——2——2
Open-angle glaucomaD005902EFO_0004190H40.1——1—12
ManiaD000087122F30——1——1
HypoxiaD000860R09.02——1——1
Brain hypoxia-ischemiaD020925EFO_1000846P91.6——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20—2———2
Substance-related disordersD019966EFO_0003890F13—1——12
Brain injuriesD001930S06.9—1———1
Marijuana abuseD002189EFO_0007191F12—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—————44
Amphetamine-related disordersD019969EFO_0004701F15————11
Major depressive disorderD003865EFO_0003761F22————11
Neurodegenerative diseasesD019636EFO_0005772G31.9————11
Uveal neoplasmsD014604EFO_1001230————11
Alzheimer diseaseD000544EFO_0000249F03————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCITICOLINE
INNciticoline
Description
CDP-choline is a member of the class of phosphocholines that is the chloine ester of CDP. It is an intermediate obtained in the biosynthetic pathway of structural phospholipids in cell membranes. It has a role as a human metabolite, a psychotropic drug, a neuroprotective agent, a Saccharomyces cerevisiae metabolite and a mouse metabolite. It is a member of phosphocholines and a member of nucleotide-(amino alcohol)s. It is functionally related to a CDP. It is a conjugate base of a CDP-choline(1+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[N+](C)(C)CCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID987-78-0
RxCUI997602
ChEMBL IDCHEMBL1618340
ChEBI ID49086
PubChem CID13804
DrugBankDB12153
UNII ID536BQ2JVC7 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,456 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
113 adverse events reported
View more details